Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 11, 2016 (11 years ago)

Lyrica (pregabalin)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Lyrica (pregabalin) capsules, 50 mg, 90-count bottle, Rx only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY, NY 10017, NDC 0071-1013-68

Affected NDC 0071-1013-68

Compare with the code on your package — it is the most precise check available.

Drug: Pregabalin

Recalling firm
Pfizer Inc.
NDC code
0071-1013-68
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0648-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Pregabalin recalls

See all
Class III · Low risk

Pregabalin Capsules 50mg

Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles during packaging set up. Tablet identified as pantoprazole tablet 20mg.

Ongoing Particulate / foreign matter Rising Pharma Holding, Inc. NDC 64980-411-10 D-0541-2024
Class II · Moderate risk

Pregabalin Capsules

Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient.

Terminated Failed specification Sun Pharmaceutical Industries INC NDC 47335-687-88 D-0361-2022
Class II · Moderate risk

LYRICA (pregabalin)

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. D-0552-2021

Other recalls by Pfizer Inc.

All 2016 recalls